Navigating Second-Line Treatment Decisions in CLL

Jennifer A. Woyach, MD, discusses the potential of pirtobrutinib as a second-line option for patients with CLL.

Dean discusses the role of BTK inhibitors in the management of CLL and the importance of molecular profiling for treatment rechallenge decisions.

Jennifer A. Woyach, MD, discusses when to initiate subsequent therapy in patients with CLL.

Asad Dean, MD, discusses the evolving role of pirtobrutinib in chronic lymphocytic leukemia.

Asad Dean, MD, discusses the role of pirtobrutinib in second-line CLL.